Endocrinology Vol. 140, No. 11 4972-4981
Copyright © 1999 by The Endocrine Society
Studies of the N-Terminal Region of a Parathyroid Hormone-Related Peptide(136) Analog: Receptor Subtype-Selective Agonists, Antagonists, and Photochemical Cross-Linking Agents1
Percy H. Carter,
Harald Jüppner and
Thomas J. Gardella
Endocrine Unit, Massachusetts General Hospital and Harvard
Medical School, Boston, Massachusetts 02114
Address all correspondence and requests for reprints to: Thomas J. Gardella, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114. E-mail:
gardella{at}helix.mgh.harvard.edu
 |
Abstract
|
|---|
The N-terminal regions of PTH and PTH-related peptide (PTHrP) are
involved in receptor-mediated signaling and subtype selectivity. To
better understand the molecular basis for these processes, we first
prepared a series of
[I5,W23,Y36]-PTHrP(136)NH2
analogs having stepwise deletions of residues 14 and characterized
them with the human (h)PTH-1 and hPTH-2 receptor subtypes stably
transfected in LLC-PK1 cells. Deletions beyond residue 2
caused progressive and severe losses in cAMP-signaling efficacy without
dramatically diminishing receptor-binding affinity; consistent with
this, [I5,W23]-PTHrP(536) was a potent
antagonist for both PTH receptor subtypes. We then prepared and
characterized photolabile analogs of
[I5,W23,Y36]-PTHrP(136)NH2
that were singly modified with
para-benzoyl-L-phenylalanine (Bpa)
along the first six residues. These full-length analogs exhibited
receptor subtype-selective agonism, antagonism, and photochemical
cross-linking profiles. In particular, the [Bpa2]- and
[Bpa4]-substituted analogs selectively antagonized and
preferentially cross-linked to the PTH-1 receptor and PTH-2 receptor,
respectively. These results demonstrate that the 15 region of
[I5,W23]-PTHrP(136) is critical for
activating the PTH-1 and PTH-2 receptors and suggest that the
individual residues in this region play distinct roles in modulating
the activation states of the two receptors. The cross-linking of both
agonist and antagonist ligands to these PTH receptors lays the
groundwork for identifying critical signaling determinants in the
ligand binding pocket of the receptor.
 |
Introduction
|
|---|
THE PTH/PTH-RELATED peptide receptor (PTH-1
receptor) is a member of the class II subfamily of G
protein-coupled seven-transmembrane domain receptors that includes the
receptors for secretin, calcitonin, and glucagon (1, 2, 3, 4). The PTH-1
receptor is well expressed in the kidney, bone, and growth-plate
cartilage and, together with PTH and PTH-related peptide (PTHrP),
serves important endocrine and paracrine functions that are essential
to the maintenance of blood mineral ion homeostasis and skeletal
development (5). Another member of the PTH/secretin/calcitonin family
of receptors was recently identified, the PTH-2 receptor, the
physiological role of which is not known (6). Unlike the PTH-1
receptor, the PTH-2 receptor responds to PTH but not to PTHrP (7).
For the PTH-1 receptor, the agonist peptides PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) and
PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) bind with nanomolar affinity and stimulate robust
increases (>20-fold) in intracellular cAMP. Previous studies using the
PTH-1 receptor have shown that there are two distinct regions of
functionality within these ligands; residues 1534 contribute the
majority of the binding energy (8, 9, 10), and residues 114 impart most
of the stimulatory capacity to the molecule (11, 12). The regions of
the PTH-1 receptor that are responsible for these effects have been
broadly defined using receptor chimeras (13).
A separate line of work has investigated the molecular basis for the
ligand-selectivity of the PTH-2 receptor. With this receptor, ligand
residues 5 (Ile in PTH and His in PTHrP) (14) and 23 (Trp in PTH and
Phe in PTHrP) were identified as important determinants for signaling
and binding selectivity, respectively (15). Subsequent mutational
studies have revealed several sites in the PTH-2 receptor that vary
from the PTH-1 receptor sequence and play a role in determining ligand
selectivity (16, 17, 18). Particularly relevant to the present study is the
prior demonstration that the PTHrP analog
[Ile5,Trp23,Tyr36]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)NH2
is a potent agonist for both receptor subtypes, exhibiting binding and
signaling properties equal to those of PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (15).
Several laboratories are currently employing photochemical
cross-linking methods to map the topology of the ligand-receptor
interface between PTH/PTHrP ligands and the PTH-1 receptor (19, 20, 21).
Recently, Behar et al. (22) reported the first mapping of a
photochemical cross-link between a PTH ligand and the PTH-2 receptor,
and they concluded from this study that photolabile residues at
positions 1 and 13 in the ligand contact identical sites in the PTH-1
receptor and PTH-2 receptor.
To expand the current body of data on the ligand-receptor interaction
mechanisms for both the PTH-1 receptor and PTH-2 receptor, we prepared
a series of analogs of
[I5,W23,Y36]-hPTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)NH2
and characterized their interactions with each receptor subtype. Given
the importance of the N-terminal region of the ligand in receptor
activation, we focused on this region and introduced either: 1)
stepwise deletions of residues 14; or 2) single substitutions of the
photoreactive amino acid
para-benzoyl-L-phenylalanine (Bpa) (23) at
positions one through six. The functional and biochemical properties of
these peptides reveal ligand-dependent and receptor-dependent profiles
of agonism, antagonism, and photochemical cross-linking reactivity,
which suggest that the PTH-1 receptor and PTH-2 receptor accommodate
large, hydrophobic sidechain substitutions in the N-terminal portion of
the ligand in dramatically different ways.
 |
Materials and Methods
|
|---|
Peptides
[Nle8,18,Tyr34]-bPTH(3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)NH2
{PTH(3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)} and
[Leu11,D-Trp12]-hPTHrP(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)NH2
were purchased from Bachem California (Torrance,
CA).
[Nle8,21,Tyr34]-rPTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)NH2
{PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)}, [Leu11,D-Trp12,
Trp23]-hPTHrP(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)NH2 {PTHrP(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)},
[Ile5,Trp23,Tyr36]-hPTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)NH2
{[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) or Parent}, and
all of the amino-terminally truncated and Bpa-substituted analogs of
[Ile5,Trp23,Tyr36]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)NH2
{[I5,W23]-PTHrP(X-36) and Bpa-1 through
Bpa-6; cf. Table 1
} used in
this study were prepared on a model 430A peptide synthesizer (PE Applied Biosystems, Norwalk, CT) using
N-(9-fluorenyl)methoxycarbonyl (Fmoc)-protecting group
chemistry. After global deprotection, each of these peptides was
purified by HPLC, lyophilized, reconstituted in 10 mM
acetic acid, and stored at -80 C. The purity, identity, and stock
concentration of each compound were secured by analytical HPLC, mass
spectrometry, and amino acid analysis. Radiolabeling was performed
using 125I-Na (2,200 Ci/mmol, DuPont NEN) and chloramine-T; the resultant
[125I-Tyr]-ligand was purified by HPLC.
Cell culture
Stably transfected derivatives of the porcine kidney cell
line LLC-PK1 were used for all experiments. The HKRKB7
LLC-PK1 cell line expresses the hPTH-1 receptor at
approximately 1 x 106 receptors/cell (24), and the
hPR220 LLC-PK1 cell line expresses the hPTH-2 receptor at
approximately 0.8 x 106 receptors/cell (provided by
H. Takasu and F. R. Bringhurst, Endocrine Unit, Massachusetts
General Hospital). Cells were cultured in T-75 flasks (75
mm2) in DMEM supplemented with 10% heat-inactivated FBS,
100 U/ml penicillin, and 100 mg/ml streptomycin in a humidified
atmosphere containing 95% air and 5% CO2. Cells were
subcultured in 24-well plates and, when confluent, were treated with
fresh media and shifted to 33 C for 1224 h before the assay (16, 25).
Under these conditions, cell densities at the time of assay were
2.2 ± 0.1 and 2.3 ± 0.2 million cells per single well of a
24-well plate for the HKRKB7 and hPR220 cell lines, respectively
(mean ± SE, recorded in triplicate at the time of
assay on four separate occasions).
Binding assays
Binding reactions were performed with stably transfected LLC-PK1
cells in 24-well plates. Cells were rinsed with 0.5 ml binding buffer
(50 mM Tris-HCl, 100 mM NaCl, 5 mM
KCl, 2 mM CaCl2, 5% heat-inactivated horse
serum, 0.5% FBS, adjusted to pH 7.7 with HCl), and treated
successively with 100 µl binding buffer, 100 µl binding buffer
containing various amounts of unlabeled competitor ligand, and 100 µl
binding buffer containing ca. 100,000 cpm of 125I-tracer
(ca. 26 fmol; final vol = 300 µl). Incubations were at room
temperature for 2 h, except for homologous binding experiments,
which were performed at 4 C for 6 h to minimize effects of
G-protein coupling and receptor internalization. Cells were then placed
on ice, the binding medium was removed, and the monolayer was rinsed
three times with 0.5 ml cold binding buffer. The cells were
subsequently lysed with 0.5 ml 5N NaOH and counted for
radioactivity. The nonspecific binding for each experiment was
determined by competition with a 1-µM dose of unlabeled
rPTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) or [I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36). The
maximum specific binding (B0) was the total
radioactivity bound in the absence of unlabeled PTH ligand, corrected
for nonspecific binding. Binding IC50 values were
determined using nonlinear regression (see below).
cAMP stimulation
Stimulation of stably transfected LLC-PK1 cells was
performed in 24-well plates. Cells were rinsed with 0.5 ml binding
buffer and treated with 200 µl cAMP assay buffer (DMEM containing 2
mM 3-isobutyl-1-methylxanthine, 1 mg/ml BSA, 35
mM HEPES-NaOH, pH 7.4) and 100 µl of binding buffer
containing varying amounts of peptide analog (final vol = 300
µl). The medium was removed after incubation for 1 h at room
temperature, and the cells were frozen (-80 C), lysed with 0.5 ml 50
mM HCl, and refrozen (-80 C). The cAMP content of the
diluted lysate was determined by RIA. Where possible, cAMP
EC50 values were determined using nonlinear regression (see
below).
Antagonism studies
The cAMP stimulation protocol described above was used for
antagonist studies, with some minor modifications. Cells were rinsed
with 0.5 ml binding buffer and treated successively with 100 µl
binding buffer containing varying doses of the candidate antagonist
peptide, 100 µl cAMP assay buffer, and 100 µl cAMP assay buffer
containing varying doses of rPTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (final vol = 300 µl).
Cells were incubated for 30 min at room temperature and processed as
above. The
[L11,D-W12,W23]-PTHrP(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)
control antagonist inhibited PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) agonist action with both PTH
receptors (see Fig. 5
), and with potency similar to that of the
antagonist [L11, D-W12]-PTHrP(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)
described by Nutt et al. (26) (data not shown). The dose of
an antagonist that inhibited the PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)-mediated cAMP response by
50% (IC50A) was calculated as described below.
Data calculation
All calculations were performed using Excel (Microsoft Corp., Redmond, WA). Nonlinear regression analysis of
binding and cAMP stimulation data were performed using four parameters,
defined as the minimum (Min), maximum (Max), midpoint
(IC50), and slope of the response curve. The
predicted response (yp) for a given dose
(x) of peptide was calculated using the following equation:
yp = Min + [(Max - Min)/(1 +
(IC50/x)slope)]. The initial
parameter values were estimated from the primary data, and the Excel
Solver function was then used to vary the four parameters to minimize
the differences between the predicted and actual responses
(least-squares method) (27). For cAMP EC50 calculations,
the Max was not constrained to the maximum response observed
(Maxobs), but was constrained to
100. Hill coefficients
were derived from homologous binding data by extracting the slope from
the linear portion of the plot of
log[B/(B0-B)]
vs. log[competitor]. Antagonist IC50A values
were calculated from the intercept of the linear portion of a plot of
log[E/(Emax-E)]
vs. log[Antagonist], where E and
Emax are the cAMP responses observed in the presence and
absence of antagonist, respectively. The statistical significance
between two data sets was determined using a one-tailed Students
t test, assuming unequal variances for the two sets.
Photochemical cross-linking
Photochemical cross-linking was carried out with
stably transfected LLC-PK1 cell lines, which had been
subcultured in 6-well plates; all manipulations were executed on ice
using chilled reagents. Cells were rinsed with 2.0 ml binding buffer,
treated with 2 ml binding buffer containing ca. 4 x
106 cpm (ca. 1 pmol) of a 125I-peptide, and
incubated at 4 C for 6 h. The medium was removed, and the cells
were rinsed twice with 1 ml binding buffer before being covered with
800 µl binding buffer. Cross-linking was induced by irradiation with
a Black-Ray UV lamp (366 nM, 700 µW/cm2,
source-to-cell = 4.5 cm) for 50 min on ice in a cold room (4 C).
The medium was withdrawn, and the cells were rinsed twice with 2 ml of
an acidic buffer (50 mM glycine, 150 mM NaCl,
adjusted to pH 2.5 with HCl) and twice with 2 ml binding buffer. The
cells were lysed with 250 µl of a Triton buffer (50 mM
Tris-HCl, 10% Triton X-100, 1 mM phenylmethylsulfonyl
fluoride, 0.05 mg/ml Bacitracin, 150 mM NaCl, pH 7.8) for
45 min at 0 C before being harvested (50 µl rinse with the Triton
buffer) and centrifuged at 2000 x g for 20 min at 4 C.
The supernatant was collected and stored at -20 C. Analysis of
equivolume aliquots from these cross-linking reactions was accomplished
using 520% SDS-PAGE (28) with subsequent autoradiography of the
dried gel at -80 C with an intensifying screen.
 |
Results
|
|---|
N-terminal deletions
To compare the importance of the N-terminal region of an agonist
peptide in mediating signal transduction with the PTH-1 receptor and
PTH-2 receptor, we synthesized analogs of
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36), which encompassed
stepwise deletions from the N-terminus (Table 1
). The excision of
residues 14 did not have a pronounced deleterious effect on the
ability of these analogs to inhibit the binding of
125I-rPTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) to either the PTH-1 or PTH-2 receptor
stably transfected in LLC-PK1 cells (Fig. 1
, A and B; Table 2
). Indeed, the truncated analog
[I5,W23]-PTHrP(3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) exhibited a 2.3-fold
higher apparent affinity for the PTH-1 receptor than did the Parent
peptide (P = 0.0006), and
[I5,W23]-PTHrP(2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) showed a 1.5-fold
higher apparent affinity for the PTH-2 receptor than did the
full-length control (P = 0.007).

View larger version (37K):
[in this window]
[in a new window]
|
Figure 1. Binding and cAMP-stimulation properties of
[I5, W23]-PTHrP(X-36) analogs. A and B,
Competition binding of the [I5,
W23]-PTHrP(X-36) analogs (peptide lengths are indicated in
the symbol key) to the PTH-1 receptor (A) and the PTH-2
receptor (B) stably expressed in LLC-PK1 cells was
performed in the presence of 125I-rPTH(1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ), as described
in Materials and Methods. Shown are data (mean ±
SE) combined from three individual experiments, each of
which was performed in duplicate on a separate day. C and D,
Stimulation of intracellular cAMP accumulation in LLC-PK1
cells expressing the PTH-1 receptor (C) and PTH-2 receptor (D) was
performed as described in Materials and Methods. Shown
are data (mean ± SE) combined from three individual
experiments, each of which was performed in duplicate on a separate
day. For some data points, the error bars are smaller
than the symbols.
|
|
In contrast to its effect on binding, stepwise removal of residues 14
progressively diminished the cAMP stimulation potency and efficacy of
the [I5,W23]-PTHrP(X-36) analogs with both
receptors (Fig. 1
, C and D; Table 2
). With the PTH-1 receptor,
[I5,W23]-PTHrP (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) and
[I5,W23]-PTHrP (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) showed 2.2-fold and
3.5-fold reductions in potency relative to the Parent peptide,
respectively (P < 0.07 for each analog vs.
Parent). The efficacy of [I5,W23]-PTHrP
(2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) was indistinguishable from that of the Parent peptide, whereas
[I5,W23]- PTHrP (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) was a partial agonist
with this receptor (Maxobs = 32% Parent,
P = 0.003). Similar effects were observed with the
PTH-2 receptor for deletion of ligand residues 1 and 2 (Fig. 1
D). The
shorter-length peptides, [I5,W23]-PTHrP
(4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) and [I5,W23]-PTHrP (5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) elicited
maximal cAMP responses with each receptor subtype that were at least
10-fold lower than that produced by
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36).
Bpa substitutions
To probe further the importance of the N-terminal region of
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) in mediating receptor
activation, we prepared a series of photolabile analogs of
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) that were singly
modified with Bpa along the first six residues (Table 1
) and examined
their functional and biochemical properties with both PTH receptors in
LLC-PK1 cells. In competition binding assays conducted with
the partial agonist 125I-bPTH(3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) and the PTH-1
receptor, all of the Bpa-substituted peptides bound more weakly than
did the Parent(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) (P < 0.03 for each analog
IC50 vs. Parent IC50), and more than
20-fold reductions in apparent binding affinity were observed with
Bpa-4 and Bpa-5 (Fig. 2A
and Table 3
). Smaller effects on binding potencies
were seen with the PTH-2 receptor, as Bpa-1 and Bpa-5 bound with
potencies that were not significantly different (P >
0.25) from that of the Parent ligand, and only Bpa-3 and Bpa-4
exhibited more than 2-fold reductions in apparent affinity, relative to
the control peptide (Fig. 2B
and Table 3
). When the agonist radioligand
125I-rPTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) was used as the tracer, the binding
profiles observed for these analogs with either receptor were similar
to those seen in the competition studies performed with
125I-bPTH (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34), in that Bpa-4 and Bpa-5 exhibited the
lowest apparent binding affinity for the PTH-1 receptor
(IC50s > 1000 nM, still representing a
>20-fold shift from the Parent), and Bpa-3 and Bpa-4 exhibited the
lowest apparent binding affinity for the PTH-2 receptor (but were still
only 2-fold weaker than the Parent peptide) (Table 3
). The binding
IC50 values obtained with the agonist tracer tended to be
higher than those measured with the partial agonist tracer.
We also conducted binding experiments under more homologous conditions,
wherein each radiolabeled analog was bound in the presence of varying
doses of the same noniodinated peptide (Fig. 2
, C and D). For the PTH-1
receptor, lower binding IC50 values were observed in the
homologous binding experiments, compared with the values observed in
the 125I-PTH(3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)-based experiments, for Bpa-1 (2.7-fold,
P = 0.002), Bpa-4 (2.8-fold, P =
0.006), and Bpa-5 (24-fold, P = 0.03). For the PTH-2
receptor, lower IC50 values were again noted for Bpa-1
(2.6-fold, P = 0.07) and Bpa-5 (2.8-fold,
P = 0.06). The improvements in the apparent binding
potencies of Bpa-1 and Bpa-5 with either receptor were even more
pronounced when the homologous competition data were compared with the
corresponding results obtained with 125I-rPTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (Table 3
). Finally, we noted that the slopes of the homologous binding curves
obtained with the PTH-1 receptor were nonparallel, and in particular,
Bpa-5 exhibited a shallower slope than did peptides of comparable
affinity (e.g. Bpa-1 and Bpa-2; Fig. 2C
). The Hill
coefficient derived for Bpa-5 (0.9 ± 0.2) was significantly
different from that of Bpa-1 (1.7 ± 0.03, P =
0.02) or Bpa-2 (1.5 ± 0.2, P = 0.04), perhaps
indicating a change in binding cooperativity (29). In contrast, the
slopes observed with the PTH-2 receptor were parallel (Fig. 2
D), and
the Hill coefficients ranged from 1.01.2.
The Bpa-substituted analogs exhibited striking differences in
their ability to stimulate cAMP generation (Fig. 3
and Table 4
). Bpa-1 was a potent and efficacious
agonist with both the PTH-1 receptor (EC50 = 8 ±
1 nM, Maxobs = 100% Parent) and PTH-2
receptor (EC50 = 17 ± 11 nM,
Maxobs = 80% Parent). In contrast, Bpa-3 and Bpa-4
were weak partial agonists with both receptors (EC50
values > 85 nM and Maxobs < 35%
Parent for each receptor). The remaining analogs exhibited receptor
subtype- selective agonist properties. Bpa-5 was a ca. 4-fold more
potent and 5-fold more efficacious agonist, relative to Parent, for the
PTH-1 receptor than for the PTH-2 receptor, despite having a binding
profile that dramatically favored the latter, particularly when assayed
by heterologous competition (see Discussion). In contrast,
Bpa-2 was an agonist/partial agonist with the PTH-2 receptor but was
nearly inactive in the cAMP assays performed with the PTH-1 receptor
(Maxobs = 10% Parent, P <
10-5). Bpa-6 was 2-fold more potent as an agonist with the
PTH-2 receptor than with the PTH-1 receptor (EC50
values = 15 ± 10 and 34 ± 1 nM,
respectively, P = 0.05), and elicited only a partial
response with the latter receptor (Maxobs = 50%
Parent, P < 10-5).

View larger version (24K):
[in this window]
[in a new window]
|
Figure 3. cAMP stimulation with
Bpa-substituted-[I5, W23]-PTHrP(1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 )
analogs. Each panel shows the response of LLC-PK1 cells
stably expressing either the PTH-1 receptor () or PTH-2 receptor
( ) to varying doses of a [I5,
W23]-PTHrP(1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 ) analog containing the Bpa substitution
indicated above the graph. Assays were performed as
described in Materials and Methods. Data shown
(mean ± SE) are combined from three individual
experiments, which were performed in duplicate on separate days. The
ordinate values are expressed as a percent of the maximum cAMP response
observed in parallel cells treated with [I5,
W23]-PTHrP(1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 ) (100 nM); for the three
combined experiments, these maximum cAMP values were 129 ± 22
pmol/well for the PTH-1 receptor and 294 ± 39 pmol/well for the
PTH-2 receptor. The corresponding basal cAMP values (not subtracted)
were 1.5 ± 0.8 and 2.1 ± 1.0 pmol/well.
|
|
Photochemical cross-linking
The ability of each of the radioiodinated photolabile
analogs to cross-link to the two PTH receptor subtypes was analyzed in
stably transfected LLC-PK1 cells (Fig. 4
). In most cases, a single band that
migrated with the mobility expected for the glycosylated PTH-1 or PTH-2
receptor (
90,000 Da) was apparent by SDS-PAGE. This photoaffinity
labeling was specific for the PTH receptors, as indicated by: 1) the
ability of a 1-µM dose of noniodinated
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) to abolish each of the
cross-links (data not shown); and 2) the difference in the mobilities
of the bands obtained from the reactions performed with the PTH-1
receptor (593 amino acids) and its lower molecular weight PTH-2
receptor counterpart (550 amino acids). With the PTH-1 receptor, Bpa-1,
Bpa-2, Bpa-3, and Bpa-5 each yielded strong band intensities; with the
PTH-2 receptor, Bpa-1, Bpa-4, Bpa-5, and Bpa-6 yielded the strongest
signals. Thus, as with the binding and cAMP signaling assays,
receptor-selective effects were observed in the photochemical
cross-linking of some of these analogs.

View larger version (89K):
[in this window]
[in a new window]
|
Figure 4. Photochemical cross-linking of Bpa analogs to the
PTH-1 and PTH-2 receptors. Shown is the cross-linking of the six
radioiodinated Bpa-substituted [I5,
W23]-PTHrP(1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 ) analogs to LLC-PK1 cells
stably expressing either the PTH-1 or PTH-2 receptor. After radioligand
binding, cells were collected and separated by SDS-PAGE (520%
gradient), under reduced conditions, and visualized by autoradiography,
as described in Materials and Methods. The position of
the Bpa-substitution is indicated at the lane origins. The differential
mobilities of the PTH-1 receptor and PTH-2 receptor complexes seen in
the 97K region of the gel are consistent with the lower MW of the PTH-2
receptor (550 amino acids vs. 593 amino acids for the
PTH-1 receptor). The autoradiograph shows a single experiment and is
representative of two other experiments performed in similar fashion.
|
|
Antagonism of PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)
The strong dissociation of apparent binding affinity and signaling
potency observed for several of the Bpa-substituted
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) analogs suggested that
these compounds might act as competitive antagonists. This hypothesis
was confirmed upon testing four of these analogs and a PTHrP(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)
control peptide (each at 1 µM) for the ability to inhibit
the stimulation of the PTH-1 receptor or PTH-2 receptor by a
half-maximal stimulatory dose (3.3 nM) of PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (Fig. 5
). This assay revealed that Bpa-2 and
Bpa-4 were antagonists, but, in contrast to the truncated PTHrP(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)
analog, these full-length peptides exhibited signs of receptor-subtype
selectivity. A similar analysis of
[I5,W23]-PTHrP(3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36), -(436), and -(536)
revealed that [I5,W23]-PTHrP(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) more
efficiently antagonized the actions of PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) on both receptor
subtypes than did the other two N-terminally truncated analogs (data
not shown).
When tested against a full-range dose-response curve of PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) with
the PTH-1 receptor, a 1-µM dose of either Bpa-2 or
[I5,W23]-PTHrP(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) increased the
EC50 of the PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) response by 8- to 10-fold (Fig. 6A
). Inhibition of the PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)
response by the PTH-1 receptor partial agonist Bpa-4 was not detected
with the PTH-1 receptor (Fig. 6A
). The dose of peptide
(IC50A) that achieved 50% inhibition of the response
elicited by 3.3 nM PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) on the PTH-1 receptor was
0.32 ± 0.07 µM for Bpa-2 and 0.27 ± 0.08
µM for [I5,W23]-PTHrP(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)
(Fig. 6C
); these two peptides were both 10-fold more potent antagonists
than [L11, D-W12,
W23]-PTHrP(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) (IC50A = 4.6 ±
1.0 µM, P = 0.02 vs. Bpa-2 or
(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36), Fig. 6C
). The maximum inhibition observed for Bpa-2 (65%, at
1 µM) differed significantly (P <
0.0001) from that attained by
[I5,W23]-(536) (90% at 3 µM)
(Fig. 6C
). With the PTH-2 receptor, a 1-µM dose of either
Bpa-4 or [I5,W23]-PTHrP(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) altered the
response to only low doses of PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (e.g. <10
nM) and did not alter the EC50 of the
PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) dose-response curve (Fig. 6
B). Although Bpa-2 was a weak or
partial agonist with the PTH-2 receptor, it did not antagonize the
actions of PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) with this receptor (Fig. 6B
). Bpa-4,
[I5,W23]-PTHrP(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36), and [L11,
D-W12, W23]-PTHrP(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) each inhibited the
response induced by 3.3 nM PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) on the PTH-2 receptor
with similar potencies (IC50A values = ca. 3
µM, P > 0.25, Fig. 6D
).

View larger version (30K):
[in this window]
[in a new window]
|
Figure 6. Antagonist properties of N-terminally-truncated
and Bpa-substituted [I5, W23]-PTHrP analogs.
A and B, The ability of a single dose of Bpa-2, Bpa-4, or
[I5, W23]-PTHrP(5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 ) to shift the
PTH(1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) dose-response in LLC-PK1 cells expressing either
the PTH1 receptor (A) or PTH-2 receptor (B) is shown. Stimulation of
cAMP accumulation by varying doses of PTH(1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) was performed in the
absence (control) or presence of a 1-µM dose of the
candidate antagonist peptide indicated in the symbol
key. Shown are data (mean ± SE) combined from
two individual experiments, each of which was performed in duplicate on
a separate day, as described in Materials and Methods. C
and D, The ability of varying doses of Bpa-2, Bpa-4, [I5,
W23]-PTHrP(5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 ), or [L11,
D-W12, W23]-PTHrP(7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 ) to inhibit the cAMP
response induced by a single dose (3.3 nM) of PTH(1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 ) in
LLC-PK1 cells expressing the PTH1 receptor (C) or PTH-2
receptor (D) is shown. Symbols for antagonist peptides are shown in the
key. Data (mean ± SE) were combined
from three individual experiments, each of which was performed in
duplicate on a separate day, as described in Materials and
Methods. The basal cAMP values from unstimulated cells were
less than 5 pmol/well and were not subtracted from the data.
|
|
 |
Discussion
|
|---|
Most of the PTH receptor antagonists that have been described to
date are N-terminally truncated analogs such as PTH (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) and
[L11,D-W12]-PTHrP(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) (26, 30).
Accordingly, our study on the ability of
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) to activate both the
PTH-1 receptor and PTH-2 receptor commenced with the functional
analysis of a series of N-terminally truncated peptides. Deletion of
residue 1 (alanine) from
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) had only a small effect
on the cAMP-stimulation response, with either PTH receptor subtype
stably expressed at high levels in LLC-PK1 cells. This
result contrasts with previous reports in which PTH analogs lacking
residue 1 were found to be weak agonists (31, 32); however, these
studies employed endogenously expressed rat PTH-1 receptors. In accord
with these earlier reports, we found that
[I5,W23]-PTHrP(2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) was ca. 5-fold less
potent and 2-fold less efficacious, relative to
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36), in stimulating cAMP in
rat osteosarcoma cells (ROS-17/2.8, data not shown), which
endogenously express PTH-1 receptors at 48,000 Rc/cell (33). Further
stepwise deletion of residues 24 in
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) led to progressive
losses in cAMP-signaling efficacy in the transfected
LLC-PK1 cells of the current study; and
[I5,W23]-PTHrP(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) was devoid of signaling
activity with either the PTH-1 receptor or PTH-2 receptor. These losses
were not accompanied by parallel reductions in binding affinity, such
that [I5,W23]-PTHrP(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) was a potent
antagonist of PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)-induced cAMP signaling for both the PTH-1
receptor and PTH-2 receptor. These results demonstrate the importance
of residues 24 of [I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) in
activating both PTH receptor subtypes.
To further explore the role of the N-terminal residues of
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) in receptor activation,
we adopted a photochemical cross-linking approach. Although a number of
different photolabile amino acids are known (34), we chose to employ
para-benzoyl-L-phenylalanine (Bpa) for our
study, because the precursor, (S)-Bpa, is readily available
and is compatible with the Fmoc amino acid protection scheme for
peptide synthesis. In addition, Bpa-substituted peptides frequently
exhibit high photochemical cross-linking efficiencies (23, 34). Several
groups have used the Bpa modification in cross-linking studies of the
PTH receptors (19, 22, 35) and one other Class II receptor (36). In
particular, Bissello and co-workers have recently reported on
PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) analogs that contain Bpa at positions 16 and have shown
that
[Bpa1,Nle8,18,Arg13,26,27,L-2-Nal23,Tyr34]-bPTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)NH2
cross-links to a site in the third extracellular loop of the PTH-1 and
PTH-2 receptors (21, 22).
The functional consequences of introducing the large, hydrophobic
benzophenone sidechain of Bpa into the N-terminal region of
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) were strongly position
dependent. Thus, Bpa-1 was a potent and fully efficacious agonist for
both receptor subtypes, whereas Bpa-3 and Bpa-4 exhibited reduced
binding and signaling capabilities with both receptors. Substitution of
Bpa at positions 2, 5, and 6 resulted in peptides that showed a
dissociation of receptor-binding affinity and signaling potency; these
effects were dependent on the PTH receptor subtype examined.
Previous studies with the PTH-1 receptor have shown that certain
natural substitutions in the N-terminal region of PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) impair
cAMP signaling more than receptor-binding affinity (37, 38), thus
indicating the potential for full-length PTH receptor antagonists. We
found that Bpa-2 was a potent antagonist with the PTH-1 receptor, and
that Bpa-4 was an antagonist with the PTH-2 receptor. The ability of
Bpa-2 to inhibit PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) activity on the PTH-1 receptor is
reminiscent of the antagonist action of
[Arg2]-PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34), although the efficacy of the latter
antagonist depends on the species of PTH-1 receptor used (39), whereas
the effectiveness of Bpa-2 does not (data not shown). Although we have
previously reported that [W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) (histidine at
position 5) is a receptor-subtype selective antagonist for the
PTH-2 receptor (15), the ability of an analog with a position 4
modification (e.g. Bpa-4) to antagonize the PTH-2 receptor
has not, to our knowledge, been described heretofore. In contrast to
Bpa-2 and Bpa-4, the N-terminally truncated antagonists
[L11,D-W12,W23]-PTHrP(7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) and
[I5,W23]-PTHrP(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) did not effectively
discriminate between the two PTH receptors.
Each of the N-terminal Bpa-substituted PTHrP analogs studied here
efficiently cross-linked to at least one of the PTH receptor subtypes.
Different patterns of cross-linking intensities were observed with the
PTH-1 receptor and PTH-2 receptor for this series of analogs. These
patterns of subtype-selective cross-linking likely reflect variations
in the local receptor environments of each different Bpa benzophenone
sidechain at the time of UV irradiation. Importantly, the photolabile
Bpa-2 and Bpa-4 analogs strongly cross-linked to the receptors for
which they functioned as antagonists. This finding suggests the
possibility that contact between the benzophenone sidechain and the
receptor is responsible for the observed antagonism, either because of
a direct steric inhibition of receptor conformational change or the
inducement of indirect allosteric constraints.
For both the PTH-1 receptor and PTH-2 receptor, Bpa-1 and Bpa-5 bound
with higher apparent affinity when analyzed by homologous competition
methods than when assayed by heterologous competition with
125I-PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) or 125I-PTH(3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34). These
differences could indicate that the two Bpa-substituted analogs use a
subset(s) of the receptor sites or states used by PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34).
Consistent with this hypothesis, Scatchard transformation of the
homologous binding data revealed that, for either receptor subtype, the
number of binding sites estimated for Bpa-1 and Bpa-5 were similar to
each other but 3-fold lower (P < 0.05) than those
calculated for PTH(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34) or the other Bpa analogs (data not shown).
Nevertheless, the results indicate that caution be used when
interpreting the data derived from the mapping of cross-linking sites
for Bpa1- and
Bpa5-[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36), and
highlight the value of homologous competition experiments for analyzing
the binding of photolabile peptide analogs.
The objective of the present study was to elucidate further the
chemical basis for the modulation of ligand-induced receptor activation
through the use of new N-terminally truncated and Bpa-substituted PTHrP
analogs. Taken together, our data show that: 1) residues 24 of
[I5,W23]-PTHrP(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) play critical roles in
activating both the PTH-1 receptor and PTH-2 receptor; 2) the insertion
of residues containing large, hydrophobic sidechains into the
N-terminal region of this peptide generates position-dependent
receptor-specific effects on binding and signaling; and 3) both
N-terminally truncated and full-length PTHrP analogs can serve as
potent antagonists for these receptors. Because receptor/ligand
complexes derived from both photolabile agonists (Bpa-1/PTH-1 receptor,
Bpa-6/PTH-2 receptor) and antagonists (Bpa-2/PTH-1 receptor,
Bpa-4/PTH-2 receptor) have been obtained, these analogs could help in
probing the differences between the active and inactive forms of the
PTH receptors. Future studies will focus on mapping these
receptor/ligand contacts and thus should complement the ongoing efforts
to analyze different receptor states using receptor mutagenesis methods
(16, 17, 39).
 |
Acknowledgments
|
|---|
We gratefully acknowledge Michael D. Luck for expert technical
assistance, Ashok Khatri for peptide synthesis and analysis, Henry T.
Keutmann for a critical reading of the manuscript, and Murat Bashtepe
for insightful discussion.
 |
Footnotes
|
|---|
1 Funding was provided by the National Institutes of Health Grant
DK-11794. 
Received March 8, 1999.
 |
References
|
|---|
-
Kolakowski L 1994 GCRDb: a G-protein-coupled
receptor database. Recept Chan 2:17[Medline]
-
Abou-Samra AB, Jüppner H, Force T, Freeman M,
Kong XF, Schipani E, Urena P, Richards J, Bonventre JV, Potts Jr JT,
Kronenberg HM, Segre GV 1992 Expression cloning of a common
receptor for parathyroid hormone and parathyroid hormone-related
peptide from rat osteoblast-like cells: a single receptor stimulates
intracellular accumulation of both cAMP and inositol triphosphates and
increases intracellular free calcium. Proc Natl Acad Sci USA 89:27322736[Abstract/Free Full Text]
-
Jüppner H, Abou-Samra A-B, Freeman M, Kong X-F,
Schipani E, Richards J, Kolakowski Jr LF, Hock J, Potts Jr JT,
Kronenberg HM, Segre GV 1991 A G protein-linked receptor for
parathyroid hormone and parathyroid hormone-related peptide. Science 254:10241026[Abstract/Free Full Text]
-
Segre GV, Goldring SR 1993 Receptors for secretin,
calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive
intestinal peptide, glucagon-like peptide 1, growth hormone-releasing
hormone, and glucagon belong to a newly discovered G protein-linked
receptor family. Trends Endocrinol Metab 4:309314[CrossRef][Medline]
-
Kronenberg H, Abou-Samra A, Bringhurst F, Gardella T,
Jüppner H, Segre G 1997 The PTH/PTHrP receptor: one receptor
for two ligands. In: Thakker R (ed) Genetics of Endocrine and Metabolic
Disorders. Chapman & Hall, London, pp 389420
-
Usdin T, Bonner T, Harta G, Mezey E 1996 Distribution of parathyroid hormone-2 receptor messenger ribonucleic
acid in rat. Endocrinology 137:42854297[Abstract]
-
Usdin T, Gruber C, Bonner T 1995 Identification
and functional expression of a receptor selectively recognizing
parathyroid hormone, the PTH2 receptor. J Biol Chem 270:1545515458[Abstract/Free Full Text]
-
Nussbaum SR, Rosenblatt M, Potts Jr JT 1980 Parathyroid hormone/renal receptor interactions: demonstration of two
receptor-binding domains. J Biol Chem 255:1018310187[Free Full Text]
-
Caulfield MP, McKee RL, Goldman ME, Duong LT, Fisher
JE, Gay CT, DeHaven PA, Levy JJ, Roubini E, Nutt RF, Chorev M,
Rosenblatt M 1990 The bovine renal parathyroid hormone (PTH)
receptor has equal affinity for two different amino acid sequences: the
receptor binding domains of PTH and PTH-related protein are located
within the 1434 region. Endocrinology 127:8387[Abstract/Free Full Text]
-
Abou-Samra A-B, Uneno S, Jüppner H, Keutmann HT,
Potts Jr JT, Segre GV, Nussbaum SR 1989 Non-homologous sequences
of parathyroid hormone and the parathyroid hormone related peptide bind
to a common receptor on ROS 17/2.8 cells. Endocrinology 125:22152217[Abstract/Free Full Text]
-
McKee RL, Goldman ME, Caulfield MP, DeHaven PA, Levy JJ,
Nutt RF, Rosenblatt M 1988 The 734 fragment of human
hypercalcemia factor is a partial agonist/antagonist for parathyroid
hormone-stimulated cAMP production. Endocrinology 122:30083010[Abstract/Free Full Text]
-
Luck M, Carter P, Gardella T 1999 The (114)
fragment of parathyroid hormone (PTH) activates intact and
amino-terminally truncated PTH-1 receptors. Mol Endocrinol 13:670680[Abstract/Free Full Text]
-
Bergwitz C, Gardella T, Flannery M, Potts JJ, Kronenberg
H, Goldring S, Jüppner H 1996 Full activation of chimeric
receptors by hybrids between parathyroid hormone and calcitonin:
evidence for a common pattern of ligand-receptor interaction. J
Biol Chem 271:2646926472[Abstract/Free Full Text]
-
Behar V, Nakamoto C, Greenberg Z, Bisello A, Suva LJ,
Rosenblatt M, Chorev M 1996 Histidine at position 5 is the
specificity "switch" between two parathyroid hormone receptor
subtypes. Endocrinology 137:42174224[Abstract]
-
Gardella T, Luck M, Jensen G, Usdin T, Jüppner
H 1996 Converting parathyroid hormone-related peptide (PTHrP) into
a potent PTH-2 receptor agonist. J Biol Chem 271:1988819893[Abstract/Free Full Text]
-
Bergwitz C, Jusseaume S, Luck M, Jüppner H,
Gardella T 1997 Residues in the membrane-spanning and
extracellular loop regions of the PTH-2 receptor determine signaling
selectivity for PTH and PTH-related peptide. J Biol Chem 272:2886128868[Abstract/Free Full Text]
-
Turner P, Mefford S, Bambino T, Nissenson R 1998 Transmembrane residues together with the amino terminus limit the
response of the parathyroid hormone (PTH) 2 receptor to PTH-related
peptide. J Biol Chem 273:38303837[Abstract/Free Full Text]
-
Clark J, Bonner T, Kim A, Usdin T 1998 Multiple
regions of ligand discrimination revealed by parathyroid hormone 2
(PTH2) and PTH/PTH-related peptide (PTHrP) receptors. Mol Endocrinol 12:193206[Abstract/Free Full Text]
-
Mannstadt M, Luck M, Gardella T, Jüppner H 1998 Evidence for a ligand interaction site at the amino-terminus of
the parathyroid hormone (PTH)/PTH-related protein receptor from
cross-linking and mutational studies. J Biol Chem 273:1689016896[Abstract/Free Full Text]
-
Adams A, Bisello A, Chorev M, Rosenblatt M, Suva L 1998 Arginine 186 in the extracellular N-terminal region of the human
parathyroid hormone 1 receptor is essential for contact with position
13 of the hormone. Mol Endocrinol 12:16731683[Abstract/Free Full Text]
-
Bisello A, Adams AE, Mierke D, Pellegrini M, Rosenblatt
M, Suva L, Chorev M 1998 Parathyroid hormone-receptor interactions
identified directly by photocross-linking and molecular modeling
studies. J Biol Chem 273:2249822505[Abstract/Free Full Text]
-
Behar V, Bisello A, Rosenblatt M, Chorev M 1998 Direct mapping of the interface of PTH and the PTH2 receptor by
photoaffinity cross-linking. Bone 23:S569 (Abstract)
-
Dorman G, Prestwich GD 1994 Benzophenone
photophores in biochemistry. Biochemistry 33:56615673[CrossRef][Medline]
-
Takasu H, Guo J, Bringhurst F 1999 Dual signaling
and ligand selectivity of the human PTH/PTHrP receptor. J Bone
Miner Res 14:1120[CrossRef][Medline]
-
Abell A, Liu X, Segaloff D 1996 Deletions of
portions of the extracellular loops of the lutropin/choriogonadotropin
receptor decrease the binding affinity for ovine luteinizing hormone,
but not human choriogonadotropin, by preventing the formation of mature
cell surface receptor. J Biol Chem 271:45184527[Abstract/Free Full Text]
-
Nutt RF, Caulfield MP, Levy JJ, Gibbons SW, Rosenblatt
M, McKee RL 1990 Removal of partial agonism from parathyroid
hormone (PTH)-related protein-(734)NH2 by substitution of
PTH amino acids at positions 10 and 11. Endocrinology 127:491493[Abstract/Free Full Text]
-
Bowen W, Jerman J 1995 Nonlinear regression using
spreadsheets. Trends Pharmacol Sci 16:413417[CrossRef][Medline]
-
Laemmli U 1970 Cleavage of structural proteins
during the assembly of the head of bacteriophage T4. Nature 227:680685[CrossRef][Medline]
-
Wells J 1992 Analysis and interpretation of binding
at equilibrium. In: Hulme E (ed) Receptor-Ligand Interactions.
IRL Press, New York, pp 289394
-
Horiuchi N, Holick MF, Potts Jr JT, Rosenblatt M 1983 A parathyroid hormone inhibitor in vivo: design and
biologic evaluation of a hormone analog. Science 220:10531055[Abstract/Free Full Text]
-
Marx U, Adermann K, Bayer P, Meyer M, Forssmann W-G,
Rösch P 1998 Structure-activity relation of the NH2-terminal
human parathyroid hormone fragments. J Biol Chem 273:43084316[Abstract/Free Full Text]
-
Tregear GW, Van Rietschoten J, Greene E, Keutmann HT,
Niall HD, Reit B, Parsons JA, Potts Jr JT 1973 Bovine parathyroid
hormone: minimum chain length of synthetic peptide required for
biological activity. Endocrinology 93:13491353[Abstract/Free Full Text]
-
Shigeno C, Hiraki Y, Westerberg DP, Potts Jr JT, Segre
GV 1988 Photoaffinity labelling of parathyroid hormone receptors
in clonal rat osteosarcoma cells. J Biol Chem 263:38643871[Abstract/Free Full Text]
-
Weber P, Beck-Sickinger A 1997 Comparison of the
photochemical behavior of four different photoactivatable probes. J
Peptide Res 49:375383[Medline]
-
Nakamoto C, Behar V, Chin KR, Adams AE, Suva LJ,
Rosenblatt M, Chorev M 1995 Probing the bimolecular interactions
of parathyroid hormone with the human parathyroid hormone/parathyroid
hormone-related protein receptor 1. Design, synthesis and
characterization of photoreactive benzophenone-containing analogs of
parathyroid hormone. Biochemistry 34:1054610552[CrossRef][Medline]
-
Dong M, Wang Y, Pinon D, Hadac E, Miller L 1999 Demonstration of a direct interaction between residue 22 in the
carboxyl-terminal half of secretin and the amino-terminal tail of the
secretin receptor using photoaffinity labeling. J Biol Chem 274:903909[Abstract/Free Full Text]
-
Cohen FE, Strewler GJ, Bradley MS, Carlquist M, Nilsson
M, Ericsson M, Ciardelli TL, Nissenson RA 1991 Analogues of
parathyroid hormone modified at positions 3 and 6: effects on receptor
binding and activation of adenylyl cyclase in kidney and bone. J
Biol Chem 266:19972004[Abstract/Free Full Text]
-
Gardella TJ, Axelrod D, Rubin D, Keutmann HT, Potts Jr
JT, Kronenberg HM, Nussbaum SR 1991 Mutational analysis of the
receptor-activating region of human parathyroid hormone. J Biol
Chem 266:1314113146[Abstract/Free Full Text]
-
Gardella TJ, Jüppner H, Wilson AK, Keutmann HT,
Abou-Samra AB, Segre GV, Bringhurst FR, Potts Jr JT, Nussbaum SR,
Kronenberg HM 1994 Determinants of [Arg2]PTH-(134) binding and
signaling in the transmembrane region of the parathyroid hormone
receptor. Endocrinology 135:11861194[Abstract]
This article has been cited by other articles:

|
 |

|
 |
 
T. Dean, A. Linglart, M. J. Mahon, M. Bastepe, H. Juppner, J. T. Potts Jr., and T. J. Gardella
Mechanisms of Ligand Binding to the Parathyroid Hormone (PTH)/PTH-Related Protein Receptor: Selectivity of a Modified PTH(1-15) Radioligand for G{alpha}S-Coupled Receptor Conformations
Mol. Endocrinol.,
April 1, 2006;
20(4):
931 - 943.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Murray, L. G. Rao, P. Divieti, and F. R. Bringhurst
Parathyroid Hormone Secretion and Action: Evidence for Discrete Receptors for the Carboxyl-Terminal Region and Related Biological Actions of Carboxyl- Terminal Ligands
Endocr. Rev.,
February 1, 2005;
26(1):
78 - 113.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Shimizu, T. Dean, J. C. Tsang, A. Khatri, J. T Potts Jr, and T. J. Gardella
Novel Parathyroid Hormone (PTH) Antagonists That Bind to the Juxtamembrane Portion of the PTH/PTH-related Protein Receptor
J. Biol. Chem.,
January 21, 2005;
280(3):
1797 - 1807.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. C. Gensure, N. Shimizu, J. Tsang, and T. J. Gardella
Identification of a Contact Site for Residue 19 of Parathyroid Hormone (PTH) and PTH-Related Protein Analogs in Transmembrane Domain Two of the Type 1 PTH Receptor
Mol. Endocrinol.,
December 1, 2003;
17(12):
2647 - 2658.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Eichinger, N. Fiaschi-Taesch, T. Massfelder, S. Fritsch, M. Barthelmebs, and J.-J. Helwig
Transcript Expression of the Tuberoinfundibular Peptide (TIP)39/PTH2 Receptor System and Non-PTH1 Receptor-Mediated Tonic Effects of TIP39 and Other PTH2 Receptor Ligands in Renal Vessels
Endocrinology,
August 1, 2002;
143(8):
3036 - 3043.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. John, M. Arai, D. A. Rubin, K. B. Jonsson, and H. Juppner
Identification and Characterization of the Murine and Human Gene Encoding the Tuberoinfundibular Peptide of 39 Residues
Endocrinology,
March 1, 2002;
143(3):
1047 - 1057.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. C. Gensure, P. H. Carter, B. D. Petroni, H. Juppner, and T. J. Gardella
Identification of Determinants of Inverse Agonism in a Constitutively Active Parathyroid Hormone/Parathyroid Hormone-related Peptide Receptor by Photoaffinity Cross-linking and Mutational Analysis
J. Biol. Chem.,
November 9, 2001;
276(46):
42692 - 42699.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Shimizu, P. H. Carter, A. Khatri, J. T. Potts Jr., and T. J. Gardella
Enhanced Activity in Parathyroid Hormone-(1-14) and -(1-11): Novel Peptides for Probing Ligand-Receptor Interactions
Endocrinology,
July 1, 2001;
142(7):
3068 - 3074.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. H. Carter, B. D. Petroni, R. C. Gensure, E. Schipani, J. T. Potts Jr., and T. J. Gardella
Selective and Nonselective Inverse Agonists for Constitutively Active Type-1 Parathyroid Hormone Receptors: Evidence for Altered Receptor Conformations
Endocrinology,
April 1, 2001;
142(4):
1534 - 1545.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. B. Jonsson, M. R. John, R. C. Gensure, T. J. Gardella, and H. Juppner
Tuberoinfundibular Peptide 39 Binds to the Parathyroid Hormone (PTH)/PTH-Related Peptide Receptor, but Functions as an Antagonist
Endocrinology,
February 1, 2001;
142(2):
704 - 709.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Shimizu, P. H. Carter, and T. J. Gardella
Autoactivation of Type-1 Parathyroid Hormone Receptors Containing a Tethered Ligand
J. Biol. Chem.,
June 23, 2000;
275(26):
19456 - 19460.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. J. Hoare, J. A. Clark, and T. B. Usdin
Molecular Determinants of Tuberoinfundibular Peptide of 39 Residues (TIP39) Selectivity for the Parathyroid Hormone-2 (PTH2) Receptor. N-TERMINAL TRUNCATION OF TIP39 REVERSES PTH2 RECEPTOR/PTH1 RECEPTOR BINDING SELECTIVITY
J. Biol. Chem.,
August 25, 2000;
275(35):
27274 - 27283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. C. Gensure, T. J. Gardella, and H. Juppner
Multiple Sites of Contact between the Carboxyl-terminal Binding Domain of PTHrP-(1-36) Analogs and the Amino-terminal Extracellular Domain of the PTH/PTHrP Receptor Identified by Photoaffinity Cross-linking
J. Biol. Chem.,
July 27, 2001;
276(31):
28650 - 28658.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Shimizu, J. Guo, and T. J. Gardella
Parathyroid Hormone (PTH)-(1-14) and -(1-11) Analogs Conformationally Constrained by alpha -Aminoisobutyric Acid Mediate Full Agonist Responses via the Juxtamembrane Region of the PTH-1 Receptor
J. Biol. Chem.,
December 21, 2001;
276(52):
49003 - 49012.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Shimizu, J. T. Potts Jr., and T. J. Gardella
Minimization of Parathyroid Hormone. NOVEL AMINO-TERMINAL PARATHYROID HORMONE FRAGMENTS WITH ENHANCED POTENCY IN ACTIVATING THE TYPE-1 PARATHYROID HORMONE RECEPTOR
J. Biol. Chem.,
July 14, 2000;
275(29):
21836 - 21843.
[Abstract]
[Full Text]
[PDF]
|
 |
|